Physician profile
Amy E Millsap
NPI 1376786566
$5,188.99
in general payments reported to CMS, 2019-2025
26 companies · $765 in 2025
The $765 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,391 · 2022: $1,011 · 2023: $1,249 · 2024: $773 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.64 |
| Education | $463.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $952.67 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $786.19 | 2021-2025 | Ilumya |
| Abbvie INC. | $739.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $413.12 | 2021-2025 | Dupixent |
| Amgen INC. | $300.74 | 2021-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $295.03 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $230.50 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $166.23 | 2021-2025 | |
| Pfizer INC. | $160.44 | 2021-2024 | |
| Lilly USA, LLC | $154.15 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $144.04 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $141.37 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $123.83 | 2021 | |
| Organogenesis INC. | $96.05 | 2021-2025 | Novachor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.18 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $77.23 | 2021-2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $63.48 | 2023 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $60.22 | 2022-2023 | Sotyktu |
| Biofrontera INC. | $46.77 | 2021-2022 | |
| Dermavant Sciences, INC. | $36.33 | 2023 | Vtama |
| Almirall LLC | $25.30 | 2023 | Klisyri |
| Galderma Laboratories, L.P. | $21.97 | 2024 | Aklief |
| Botanix Sb INC | $20.77 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $18.04 | 2022 | |
| Journey Medical Corporation | $12.84 | 2022 | |
| Strata Skin Sciences, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Millsap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.